433 related articles for article (PubMed ID: 29163851)
1. Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity.
Mittica G; Ghisoni E; Giannone G; Aglietta M; Genta S; Valabrega G
Oncotarget; 2017 Oct; 8(52):90532-90544. PubMed ID: 29163851
[TBL] [Abstract][Full Text] [Related]
2. Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?
Gargiulo P; Della Pepa C; Berardi S; Califano D; Scala S; Buonaguro L; Ciliberto G; Brauchli P; Pignata S
Cancer Treat Rev; 2016 Jul; 48():61-8. PubMed ID: 27362548
[TBL] [Abstract][Full Text] [Related]
3. Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.
Howitt BE; Shukla SA; Sholl LM; Ritterhouse LL; Watkins JC; Rodig S; Stover E; Strickland KC; D'Andrea AD; Wu CJ; Matulonis UA; Konstantinopoulos PA
JAMA Oncol; 2015 Dec; 1(9):1319-23. PubMed ID: 26181000
[TBL] [Abstract][Full Text] [Related]
4. Immune profiling of microsatellite instability-high and polymerase ε (
Wang C; Gong J; Tu TY; Lee PP; Fakih M
J Gastrointest Oncol; 2018 Jun; 9(3):404-415. PubMed ID: 29998005
[TBL] [Abstract][Full Text] [Related]
5. [Application and clinical significance of TCGA molecular classification in endometrial cancer].
Zhao LY; Dai YB; Li LW; Wang ZQ; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2021 Oct; 56(10):697-704. PubMed ID: 34823319
[No Abstract] [Full Text] [Related]
6. Immunological profiling of molecularly classified high-risk endometrial cancers identifies
Eggink FA; Van Gool IC; Leary A; Pollock PM; Crosbie EJ; Mileshkin L; Jordanova ES; Adam J; Freeman-Mills L; Church DN; Creutzberg CL; De Bruyn M; Nijman HW; Bosse T
Oncoimmunology; 2017; 6(2):e1264565. PubMed ID: 28344870
[TBL] [Abstract][Full Text] [Related]
7. Distinct mutational profile and immune microenvironment in microsatellite-unstable and
Hwang HS; Kim D; Choi J
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34607897
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors for recurrent endometrial cancer.
Mutlu L; Harold J; Tymon-Rosario J; Santin AD
Expert Rev Anticancer Ther; 2022 Mar; 22(3):249-258. PubMed ID: 35176955
[TBL] [Abstract][Full Text] [Related]
9. A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.
Bellone S; Roque DM; Siegel ER; Buza N; Hui P; Bonazzoli E; Guglielmi A; Zammataro L; Nagarkatti N; Zaidi S; Lee J; Silasi DA; Huang GS; Andikyan V; Damast S; Clark M; Azodi M; Schwartz PE; Tymon-Rosario JR; Harold JA; Mauricio D; Zeybek B; Menderes G; Altwerger G; Ratner E; Alexandrov LB; Iwasaki A; Kong Y; Song E; Dong W; Elvin JA; Choi J; Santin AD
Cancer; 2022 Mar; 128(6):1206-1218. PubMed ID: 34875107
[TBL] [Abstract][Full Text] [Related]
10. Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.
Bellone S; Bignotti E; Lonardi S; Ferrari F; Centritto F; Masserdotti A; Pettinella F; Black J; Menderes G; Altwerger G; Hui P; Lopez S; de Haydu C; Bonazzoli E; Predolini F; Zammataro L; Cocco E; Ferrari F; Ravaggi A; Romani C; Facchetti F; Sartori E; Odicino FE; Silasi DA; Litkouhi B; Ratner E; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2017 Jan; 144(1):146-152. PubMed ID: 27894751
[TBL] [Abstract][Full Text] [Related]
11. Targeted Treatment of Advanced Endometrial Cancer: Focus on Pembrolizumab.
El-Ghazzi N; Durando X; Giro A; Herrmann T
Onco Targets Ther; 2023; 16():359-369. PubMed ID: 37288137
[TBL] [Abstract][Full Text] [Related]
12. Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes.
Loupakis F; Depetris I; Biason P; Intini R; Prete AA; Leone F; Lombardi P; Filippi R; Spallanzani A; Cascinu S; Bonetti LR; Maddalena G; Valeri N; Sottoriva A; Zapata L; Salmaso R; Munari G; Rugge M; Dei Tos AP; Golovato J; Sanborn JZ; Nguyen A; Schirripa M; Zagonel V; Lonardi S; Fassan M
Oncologist; 2020 Jun; 25(6):481-487. PubMed ID: 31967692
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research.
Gadducci A; Guerrieri ME
Anticancer Res; 2017 Nov; 37(11):5955-5965. PubMed ID: 29061774
[TBL] [Abstract][Full Text] [Related]
14. Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment.
Song Y; Gu Y; Hu X; Wang M; He Q; Li Y
Onco Targets Ther; 2021; 14():4485-4497. PubMed ID: 34429613
[TBL] [Abstract][Full Text] [Related]
15. Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer.
Yamashita H; Nakayama K; Ishikawa M; Nakamura K; Ishibashi T; Sanuki K; Ono R; Sasamori H; Minamoto T; Iida K; Sultana R; Ishikawa N; Kyo S
Oncotarget; 2018 Jan; 9(5):5652-5664. PubMed ID: 29464025
[TBL] [Abstract][Full Text] [Related]
16. Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology.
Rousset-Rouviere S; Rochigneux P; Chrétien AS; Fattori S; Gorvel L; Provansal M; Lambaudie E; Olive D; Sabatier R
Biomedicines; 2021 Jun; 9(6):. PubMed ID: 34199461
[TBL] [Abstract][Full Text] [Related]
17. How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review.
Maiorano BA; Maiorano MFP; Cormio G; Maglione A; Lorusso D; Maiello E
Front Oncol; 2022; 12():844801. PubMed ID: 35494078
[TBL] [Abstract][Full Text] [Related]
18. New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere.
Bruchim I; Capasso I; Polonsky A; Meisel S; Salutari V; Werner H; Lorusso D; Scambia G; Fanfani F
Expert Opin Ther Targets; 2024; 28(1-2):29-43. PubMed ID: 38327111
[TBL] [Abstract][Full Text] [Related]
19. Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer.
Hill BL; Graf RP; Shah K; Danziger N; Lin DI; Quintanilha J; Li G; Haberberger J; Ross JS; Santin AD; Slomovitz B; Elvin JA; Eskander RN
Int J Gynecol Cancer; 2023 Apr; 33(4):504-513. PubMed ID: 36750267
[TBL] [Abstract][Full Text] [Related]
20. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma.
Di Dio C; Bogani G; Di Donato V; Cuccu I; Muzii L; Musacchio L; Scambia G; Lorusso D
Gynecol Oncol; 2023 Feb; 169():27-33. PubMed ID: 36493574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
